Corvus Pharmaceuticals Q4 2025 Earnings Preview

2026-03-11 17:35:52 ET

More on Corvus Pharmaceuticals

• Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - Slideshow
• Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon
• Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know
• Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15
• Corvus Pharmaceuticals plans $150M offering of shares and pre-funded warrants

Read the full article on Seeking Alpha

For further details see: